Straumann Holding AG (OTCMKTS:SAUHY – Get Free Report) was the target of a large decrease in short interest in July. As of July 31st, there was short interest totaling 5,152 shares, a decrease of 77.6% from the July 15th total of 23,021 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average daily volume of 79,441 shares, the days-to-cover ratio is currently 0.1 days.
Straumann Stock Down 0.9%
Shares of Straumann stock traded down $0.11 on Thursday, reaching $12.50. 6,124 shares of the company were exchanged, compared to its average volume of 137,005. Straumann has a 1-year low of $9.44 and a 1-year high of $13.61. The company’s 50-day moving average is $12.54 and its two-hundred day moving average is $11.70.
Analyst Upgrades and Downgrades
Several analysts recently weighed in on the company. BMO Capital Markets initiated coverage on Straumann in a report on Wednesday, July 8th. They issued an “outperform” rating for the company. Barclays reiterated an “overweight” rating on shares of Straumann in a research report on Thursday, June 18th. Morgan Stanley reiterated an “underweight” rating on shares of Straumann in a report on Tuesday, June 30th. Citigroup restated a “sell” rating on shares of Straumann in a research note on Thursday, July 9th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Straumann in a report on Tuesday, June 30th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold”.
About Straumann
Straumann (OTCMKTS:SAUHY) is a Swiss-based dental technology company that develops, manufactures and markets restorative, regenerative and digital solutions for dental professionals. The company’s core offerings center on implant-supported restorations and components, biomaterials used for bone and soft-tissue regeneration, and a range of prosthetic products used by dentists and dental laboratories to restore oral function and aesthetics.
In addition to implant and biomaterial product lines, Straumann provides digital dentistry solutions that support treatment planning and workflows.
See Also
- Five stocks we like better than Straumann
- Ryman Checks Into a $1.38B Hospitality Upgrade
- Axos Financial Keeps Proving the Digital Banking Model Works
- SpaceX’s First Earnings Report Only Made Wall Street More Divided
- Plug Power Charges Ahead: Margin Expansion Sparks a Rally
Receive News & Ratings for Straumann Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Straumann and related companies with MarketBeat.com's FREE daily email newsletter.
